SNDX
Syndax Pharmaceuticals Inc
$18.25
+1.90%
$1.6B
No data for this timeframe.
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders50 funds
Inst. Value$1.2B
Inst. Activity17 buys / 8 sells
Insider Activity0B / 8S
Insider Net $-$2.0M
SEC Reports5
Press Releases2
Recent Activity
Jun 12, 2026
Insider
Botwood Nicholas A.J. acquired via exercise 31,235 shares
Head of R&D, CMO @ $13.82 ($431.7K)
Jun 12, 2026
Insider
Botwood Nicholas A.J. sold 31,235 shares
Head of R&D, CMO @ $18.14 ($566.6K)
Jun 11, 2026
Press
Syndax presented 12 abstracts on revumenib at EHA 2026, including real-world data showing 82% ORR in R/R NPM1m/KMT2Ar pa
Impact 7/10
Jun 11, 2026
fda
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
<p align="center"><em>– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rat
Jun 11, 2026
Insider
Botwood Nicholas A.J. acquired via exercise 22,515 shares
Head of R&D, CMO @ $13.82 ($311.2K)
Jun 10, 2026
SEC
Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a pr
8-K — Impact 5/10
Jun 4, 2026
SEC
Syndax Pharmaceuticals filed DEFA14A definitive additional proxy materials urging shareholders to vote FOR Proposal No.
DEFA14A — Impact 4/10
Jun 4, 2026
SEC
Syndax Pharmaceuticals entered into subscription agreements to issue $250.0 million aggregate principal amount of 2.25%
8-K — Impact 5/10
Price Targets
$39.00
+113.7% upside
Strong Buy
Current $18.25
Low $29.00
Median $37.00
High $57.00
12 analysts
$29.00
$57.00
Analyst Ratings
8Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 12, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 13, 2026 | UBS | MAINTAIN | Buy → Buy |
| May 1, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 1, 2026 | Goldman Sachs | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.46 ▲ +1.4% | $-0.81 — $-0.33 | 44% YoY | 12 |
| Next Q | $-0.38 ▲ +1.2% | $-0.72 — $-0.21 | 45% YoY | 12 |
| Current FY | $-1.70 ▲ +3.0% | $-2.71 — $-1.16 | 48% YoY | 12 |
| Next FY | $-0.60 ▼ -38.7% | $-2.22 — $0.43 | 65% YoY | 11 |
Latest Reports
BULLISH
Press
7/10
Syndax presented 12 abstracts on revumenib at EHA 2026, including real-world data showing 82% ORR in R/R NPM1m/KMT2Ar pa
Jun 11, 2026
NEUTRAL
8-K
5/10
Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a pr
Jun 10, 2026
NEUTRAL
DEFA14A
4/10
Syndax Pharmaceuticals filed DEFA14A definitive additional proxy materials urging shareholders to vote FOR Proposal No.
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $192.8M | — |
| GOLDMAN SACHS GROUP INC | $116.7M | — |
| STATE STREET CORP | $103.5M | — |
| BANK OF AMERICA CORP | $99.3M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $89.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 12, 2026 | Botwood Nicholas | M | $431.7K |
| Jun 12, 2026 | Botwood Nicholas | SELL | $566.6K |
| Jun 11, 2026 | Botwood Nicholas | M | $311.2K |
| Jun 11, 2026 | Botwood Nicholas | SELL | $617.0K |
| Jun 1, 2026 | Goldan Keith | SELL | $22.4K |
50 institutional holders with $1.2B total value (49,645,956 shares) as of 2026-Q1. Top holders: BlackRock,, GOLDMAN, STATE. Net buying activity: 17 institutions added/increased vs 8 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8,254,426 | $192.8M | 16.6% | — |
| 2 | GOLDMAN SACHS GROUP INC | 4,996,787 | $116.7M | 10.1% | — |
| 3 | STATE STREET CORP | 4,430,076 | $103.5M | 8.9% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 4,249,836 | $99.3M | 8.6% | ADD +27.4% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3,822,579 | $89.3M | 7.7% | — |
| 6 | Hood River Capital Management LLC | 2,354,285 | $55.0M | 4.7% | NEW |
| 7 | FRANKLIN RESOURCES INC | 2,150,079 | $50.2M | 4.3% | — |
| 8 | Point72 Asset Management, L.P. | 1,985,547 | $46.4M | 4.0% | TRIM -59.3% |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,737,141 | $40.6M | 3.5% | — |
| 10 | BNP Paribas Asset Management Holding S.A. | 1,732,541 | $40.5M | 3.5% | ADD +25.9% |
| 11 | D. E. Shaw & Co., Inc. | 1,601,896 | $37.4M | 3.2% | — |
| 12 | TWO SIGMA INVESTMENTS, LP | 1,579,596 | $36.9M | 3.2% | ADD +60.9% |
| 13 | Nuveen, LLC | 1,494,645 | $34.9M | 3.0% | — |
| 14 | Woodline Partners LP | 1,250,760 | $29.2M | 2.5% | — |
| 15 | MORGAN STANLEY | 893,933 | $20.9M | 1.8% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 715,153 | $16.7M | 1.4% | — |
| 17 | CITADEL ADVISORS LLC | 630,942 | $14.7M | 1.3% | — |
| 18 | VANGUARD FIDUCIARY TRUST CO | 600,517 | $14.0M | 1.2% | — |
| 19 | RENAISSANCE TECHNOLOGIES LLC | 498,200 | $11.6M | 1.0% | TRIM -36.7% |
| 20 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 331,665 | $7.7M | 0.7% | DOUBLED +141.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | TRIM | 4,882,053 | 1,985,547 | -59.3% | $46.4M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 1,375,681 | 1,732,541 | +25.9% | $40.5M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | DOUBLED | 137,629 | 331,665 | +141.0% | $7.7M | 2026-Q1 |
| Invesco Ltd. | ADD | 160,525 | 252,761 | +57.5% | $5.9M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | ADD | 125,099 | 249,407 | +99.4% | $5.8M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 159,638 | 217,600 | +36.3% | $5.1M | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 515,129 | 204,845 | -60.2% | $4.8M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 87,514 | 201,777 | +130.6% | $4.7M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | TRIM | 233,871 | 145,566 | -37.8% | $3.4M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 35,630 | 123,586 | +246.9% | $2.9M | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 554,761 | 105,051 | -81.1% | $2.5M | 2026-Q1 |
| Mariner, LLC | ADD | 54,987 | 73,199 | +33.1% | $1.7M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | ADD | 47,421 | 69,059 | +45.6% | $1.6M | 2026-Q1 |
| Hudson Bay Capital Management LP | TRIM | 165,000 | 62,330 | -62.2% | $1.5M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 24,806 | 41,872 | +68.8% | $978.1K | 2026-Q1 |
| STIFEL FINANCIAL CORP | TRIM | 75,914 | 41,714 | -45.1% | $974.4K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 25,461 | 39,904 | +56.7% | $932.2K | 2026-Q1 |
| Cerity Partners LLC | ADD | 28,856 | 39,083 | +35.4% | $913.0K | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 9,707 | 38,331 | +294.9% | $895.4K | 2026-Q1 |
| HighTower Advisors, LLC | ADD | 18,940 | 37,031 | +95.5% | $865.0K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 65,280 | 28,538 | -56.3% | $666.6K | 2026-Q1 |
| Marex Group plc | ADD | 15,060 | 20,060 | +33.2% | $468.6K | 2026-Q1 |
| DnB Asset Management AS | TRIM | 29,760 | 16,652 | -44.0% | $389.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 472 | 3,209 | +579.9% | $75.0K | 2026-Q1 |
| Allworth Financial LP | ADD | 1,129 | 1,686 | +49.3% | $39.4K | 2026-Q1 |
9 unique insiders with 23 transactions. Net insider value: -$2.0M ($0.00 bought, $2.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | EXERCISE | 31,235 | $13.82 | $431.7K |
| Jun 12, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | SELL | 31,235 | $18.14 | $566.6K |
| Jun 11, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | EXERCISE | 22,515 | $13.82 | $311.2K |
| Jun 11, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | SELL | 34,280 | $18.00 | $617.0K |
| Jun 1, 2026 | Goldan Keith A. | Chief Financial Officer | SELL | 1,177 | $18.99 | $22.4K |
| Jun 1, 2026 | Metzger Michael A | Chief Executive Officer | SELL | 6,847 | $18.99 | $130.0K |
| Feb 9, 2026 | Goldan Keith A. | Chief Financial Officer | SELL | 3,410 | $21.03 | $71.7K |
| Feb 9, 2026 | Metzger Michael A | Chief Executive Officer | SELL | 17,159 | $21.03 | $360.8K |
| Feb 6, 2026 | Goldan Keith A. | Chief Financial Officer | SELL | 2,082 | $20.62 | $42.9K |
| Feb 6, 2026 | Metzger Michael A | Chief Executive Officer | SELL | 7,412 | $20.62 | $152.8K |
| Feb 4, 2026 | Jarrett Jennifer | Director | AWARD | 24,000 | — | — |
| Feb 4, 2026 | Huber Martin H. Jr. | Director | AWARD | 24,000 | — | — |
| Feb 4, 2026 | Rizo Aleksandra | Director | AWARD | 24,000 | — | — |
| Feb 4, 2026 | Metzger Michael A | Chief Executive Officer | AWARD | 73,000 | — | — |
| Feb 4, 2026 | Metzger Michael A | Chief Executive Officer | AWARD | 440,000 | $20.43 | $9.0M |
| Feb 4, 2026 | Goldan Keith A. | Chief Financial Officer | AWARD | 21,500 | — | — |
| Feb 4, 2026 | Goldan Keith A. | Chief Financial Officer | AWARD | 118,000 | $20.43 | $2.4M |
| Feb 4, 2026 | Podlesak Dennis | Director | AWARD | 48,000 | — | — |
| Feb 4, 2026 | Katkin Keith | Director | AWARD | 24,000 | — | — |
| Feb 4, 2026 | Legault Pierre | Director | AWARD | 24,000 | — | — |
| Feb 4, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | AWARD | 24,000 | — | — |
| Feb 4, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | AWARD | 144,700 | $20.43 | $3.0M |
| Jan 30, 2026 | Goldan Keith A. | Chief Financial Officer | J | 1,219 | $8.48 | $10.3K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
5/10
Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior No
Jun 10, 2026
NEUTRAL
DEFA14A
4/10
Syndax Pharmaceuticals filed DEFA14A definitive additional proxy materials urging shareholders to vo
Jun 4, 2026
NEUTRAL
8-K
5/10
Syndax Pharmaceuticals entered into subscription agreements to issue $250.0 million aggregate princi
Jun 4, 2026
NEUTRAL
DEFA14A
3/10
Syndax Pharmaceuticals filed a DEFA14A (additional definitive proxy soliciting materials) on April 3
Apr 30, 2026
NEUTRAL
PRESS-RELEASE
3/10
Syndax Pharmaceuticals announced it will report Q1 2026 financial results and provide a business upd
Apr 24, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 8 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$39.00 mean target
+113.7% upside
Strong Buy (1.15)
$29.00 Low
$57.00 High
| Metric | Value |
|---|---|
| Current Price | $18.25 |
| Target Low | $29.00 |
| Target Mean | $39.00 |
| Target Median | $37.00 |
| Target High | $57.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.15) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.46 | $-0.81 | $-0.33 | 44.2% | +1.4% | 5↑ 3↓ | $0.1B | 110.1% | 12 |
| Next Q 2026-09-30 |
$-0.38 | $-0.72 | $-0.21 | 45.0% | +1.2% | 2↑ 5↓ | $0.1B | 101.9% | 12 |
| Current FY 2026-12-31 |
$-1.70 | $-2.71 | $-1.16 | 48.2% | +3.0% | 3↑ 7↓ | $0.3B | 100.9% | 12 |
| Next FY 2027-12-31 |
$-0.60 | $-2.22 | $0.43 | 64.5% | -38.7% | 3↑ 5↓ | $0.5B | 45.3% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.463 | |
| 7d ago | $-0.459 | -0.004 |
| 30d ago | $-0.470 | +0.007 |
| 60d ago | $-0.498 | +0.035 |
| 90d ago | $-0.446 | -0.017 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 12, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 13, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 1, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 1, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 9, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 2, 2026 | Citigroup | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
fda
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
<p align="center"><em>– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with
Jun 9, 2026
short_volume
Short Volume: SNDX — 69.1% short (0.3M / 0.5M)
Short: 348,695 | Exempt: 126 | TRF Vol: 504,314 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
activist
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
<p align="justify">NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company a
Jun 4, 2026
short_volume
Short Volume: SNDX — 65.9% short (1.7M / 2.7M)
Short: 1,746,390 | Exempt: 0 | TRF Vol: 2,651,489 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
Clinical Trial
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Axatilimab (Phase 2)
Trial: MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Syndax Pharmaceuticals
Phase: Phase 2 |
Jun 2, 2026
other
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
<p align="center"><em>– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who <br>resumed revumenib post-transpla
May 21, 2026
other
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
<p align="center"><em>– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute
May 20, 2026
other
Syndax Announces Participation in Upcoming Investor Conferences
<p align="justify">NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company ad
May 15, 2026
short_volume
Short Volume: SNDX — 64.2% short (0.4M / 0.7M)
Short: 434,172 | Exempt: 0 | TRF Vol: 676,065 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
May 12, 2026
other
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
<p align="center"><em>– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes –</e
May 8, 2026
short_volume
Short Volume: SNDX — 63.1% short (0.4M / 0.6M)
Short: 407,674 | Exempt: 1 | TRF Vol: 646,524 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
May 6, 2026
other
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
<p align="justify">NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company ad
May 1, 2026
short_volume
Short Volume: SNDX — 58.4% short (1.4M / 2.3M)
Short: 1,353,299 | Exempt: 14,190 | TRF Vol: 2,318,262 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center">– <em>Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – </em></p>
Apr 30, 2026
earnings_calendar
SNDX Q1 2026 Earnings Scheduled — 2026-04-30